Sangamo Therapeutics Stock Moves to OTCID Basic with 'Q' Suffix Following Chapter 11 Bankruptcy
SGMOQ sits 90% above its 52-week low of $0.03 on light trading volume (0.4× avg).
Summary
Sangamo Therapeutics' stock has moved to the OTCID Basic Market under the symbol "SGMOQ" and its auditor was terminated, both direct consequences of its previously announced Chapter 11 bankruptcy filing.
Key Events · Legal and Risk Events · SGMOQ
-
Auditor Terminated
Ernst & Young LLP was terminated as the independent registered public accounting firm on June 25, 2026, a direct result of the company's Chapter 11 bankruptcy filing. EY's prior reports included a 'going concern' explanatory paragraph.
-
Trading on OTCID Basic Market with 'Q' Suffix
The company's common stock began trading on the OTCID Basic Market under the symbol "SGMOQ" on June 24, 2026. The 'Q' suffix explicitly indicates the company is in bankruptcy.
-
Nasdaq Delisting Appeal Pending
The company's common stock remains listed on the Nasdaq Capital Market pending an appeal of a delisting determination, though trading on Nasdaq is suspended.
Analysis · SGMOQ · Life Sciences
This filing details the formal consequences of Sangamo Therapeutics' Chapter 11 bankruptcy, including the termination of its independent auditor and the move of its common stock to the OTCID Basic Market under the symbol "SGMOQ". The "Q" suffix explicitly indicates the company is in bankruptcy, providing a clear and definitive signal of its distressed financial status to investors.
At the time of this filing, SGMOQ was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $23.6M. The 52-week trading range was $0.03 to $0.77. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.